Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parall...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fanping, Xu, Ruonan, Wang, Siyu, Xu, Zhe, Zhang, Chao, Li, Yuanyuan, Yang, Tao, Shi, Lei, Fu, Junliang, Jiang, Tianjun, Huang, Lei, Zhao, Peng, Yuan, Xin, Fan, Xing, Zhang, Ji-Yuan, Song, Jinwen, Zhang, Dawei, Jiao, Yanmei, Liu, Limin, Zhou, Chunbao, Maeurer, Markus, Zumla, Alimuddin, Shi, Ming, Wang, Fu-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450163/
https://www.ncbi.nlm.nih.gov/pubmed/32855385
http://dx.doi.org/10.1038/s41392-020-00286-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450163/
https://www.ncbi.nlm.nih.gov/pubmed/32855385
http://dx.doi.org/10.1038/s41392-020-00286-5

Ejemplares similares